Codexis uses its proprietary CodeEvolver® discovery platform to uniquely tailor next-generation biotherapeutics with transformative properties. We combine bioinformatics from thousands of protein variants with directed evolution to create intentionally designed proteins, specifically optimized for their disease indications.


We focus on developing life-changing biologic and gene therapy candidates that address the critical unmet needs of patients. Our current priorities are inborn errors of metabolism, gastrointestinal disorders, lysosomal storage diseases, and other debilitating genetic disorders with pivotal patient need.
Our pipeline is committed to the continuous advancement of therapeutic candidates with best-in-class efficacy through self-funded initiatives or in close collaboration with our valued partners.


The November issue of Nature’s Biopharma Dealmakers includes an article that highlights how our CodeEvolver® technology platform can overcome the suboptimal properties and limitations of natural proteins by generating novel biological variants with safety and efficacy profiles specifically tailored to target diseases.